**NEWS & COMMENTARY**

**Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19)**

Caroline Galeotti¹, Srini V Kaveri² & Jagadeesh Bayry²

¹Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires Rares et des Amyloses, CHU de Bicêtre, le Kremlin Bicêtre, France

²Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France

**Correspondence**

J Bayry, Institut National de la Santé et de la Recherche Médicale, Unité 1138, Centre de Recherche des Cordeliers, 15 rue de l’Ecole de Médecine, Paris F-75006, France.

E-mail: jagadeesh.bayry@crc.jussieu.fr

See also: Shao et al. Clinical & Translational Immunology 2020; e01192. https://doi.org/10.1002/cti2.1192

The coronavirus disease-19 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused widespread morbidity and mortality across the globe. Most of the affected patients depend on mechanical ventilation. The SARS-CoV-2 infection triggers massive influx of activated immune cells to the lungs causing cytokine storm and severe lung lesions.¹ Although our understanding of the pathogenesis of the disease and patient management have drastically improved recently, no specific pharmacological treatment is available yet. As cytokine storm is the major cause of morbidity and mortality, several drugs such as steroids that target inflammation, inhibitors of signalling molecules and also immunotherapies such as neutralising antibodies to IL-6 and GM-CSF; recombinant IL-1 receptor antagonist, blocking antibodies to IL-6 receptor and intravenous immunoglobulin (IVIG) have provided encouraging results.² While the aforementioned immunotherapies target a specific molecule, IVIG exerts its therapeutic benefits by several mutually nonexclusive mechanisms targeting diverse arms of the inflammatory immune response.

**INTRAVENOUS IMMUNOGLOBULIN**

Intravenous immunoglobulin, a therapeutic normal IgG isolated from the pooled plasma of several thousand healthy donors, is one of the frequently used immunotherapeutic molecules for treating various autoimmune and inflammatory diseases.³ In general, the dose of IVIG for the therapeutic purposes is 2 g kg⁻¹ infused either one, two or five consecutive days. In addition to clinically approved pathological conditions including Kawasaki disease, immune thrombocytopenic purpura, inflammatory myopathies, Guillain-Barré syndrome, graft-vs-host disease and blistering diseases, IVIG has been explored in over 100 diseases as an off-label drug. IVIG exerts its therapeutic benefits in autoimmune diseases by several mutually nonexclusive mechanisms targeting both soluble and cellular mediators of the inflammatory immune response. These mechanisms include complement scavenging, neutralisation of autoantibodies by idotypic network; enhancement of degradation of autoantibodies by neonatal Fc receptor saturation; inhibition of activation of various innate immune cells including dendritic cells, monocytes, macrophages and neutrophils, and secretion of inflammatory mediators; suppression of effector T helper cells Th1 and Th17, and reciprocal enhancement of immunoprotective regulatory T cells (Tregs); and blockade of B-cell activation.⁴ These multitude anti-inflammatory mechanisms and proven safety record of the drug...
prompted clinical evaluation of IVIG in the management of severe and critically ill COVID-19 patients.

IVIG IMMUNOTHERAPY FOR THE TREATMENT OF COVID-19

In a recent article published in *Clinical & Translational Immunology*, Shao et al.⁵ presented a multicentre retrospective cohort study evaluating the efficacy of IVIG in 325 severe and critically ill COVID-19 patients admitted to hospitals in southern China between December 2019 and March 2020. In their cohort, 174 patients (64% male, median age 61 years) received IVIG, while 151 patients (51% male, median age 56 years) did not receive this therapy. Patients received IVIG at a dose of 0.1–0.5 g kg⁻¹ day⁻¹ for the duration of 5–15 days. Additional therapies include antibiotics, anti-viral drugs and steroids as per guidelines of China. Their analyses showed that early administration (<7 days postadmission) of high-dose (>15 g day⁻¹) IVIG improves the prognosis of critical-type patients with COVID-19.

This multicentre study has certain limitations. First, it is a retrospective study. Second, a wide range of IVIG dose and varying duration of treatment were employed. Third, there is a lack of analyses of various inflammatory cytokines and immune cells. Randomised, placebo-controlled clinical studies with mechanistic insight are critical in assessing the full spectrum of IVIG efficacy and clinical studies with mechanistic insight are critical in assessing the full spectrum of IVIG efficacy and window of treatment in COVID-19. As anti-inflammatory effects of IVIG normally rely on a high dose (2 g kg⁻¹), this dosage should be considered for future clinical trials.

Currently, data are available from seven reports including the multicentre study of Shao et al.⁵ that explored IVIG immunotherapy in the management of COVID-19 (Table 1).⁵⁻¹¹ These studies are mostly case series or retrospective, with an exception of one study that was randomised open-label trial. Although retrospective, data from Shao et al. included large number of COVID-19 patients compared to other studies, and hence, data are more reliable.⁵ Importantly, a retrospective study of Xie et al.⁹ also confirmed the therapeutic benefits of IVIG if therapy is initiated early. Another report documented that short-term moderate-dose corticosteroid plus IVIG (20 g day⁻¹) might effectively benefit COVID-19 patients who did not respond to low-dose therapy (10 g day⁻¹).⁶ The only randomised controlled study on IVIG also combined methylprednisolone.⁸ In view of the corticosteroid combination, it is difficult to evaluate the therapeutic benefits of IVIG in these trials. Another study combined IVIG with anakinra, a recombinant modified IL-1 receptor antagonist.¹¹ Thus, in view of associated therapies, the therapeutic benefits of IVIG have to be evaluated carefully. It is important to note that studies in autoimmune and inflammatory diseases have reported better outcomes if IVIG is combined with steroids. Also, IVIG has steroid-sparing effects.

POSSIBLE MECHANISMS OF ACTION OF IVIG IN COVID-19

How does IVIG benefit COVID-19 patients? Although the mechanisms are not yet precisely understood, reduction in the inflammatory mediators following IVIG therapy (Table 1) suggests that IVIG might target cytokine storm in severe and critically ill COVID-19 patients by complement scavenging, inhibition of innate immune cells and effector T-cell activation, and expansion of Tregs (Figure 1). Although current batches of IVIG could neutralise seasonal coronavirus, they lack cross-neutralising antibodies to SARS-CoV-2.¹² Therefore, passive virus neutralisation appears to be not responsible for the beneficial effects of IVIG. Recently, it has been found that SARS-CoV-2 encodes a superantigen motif near its S1/S2 cleavage site that might trigger cytokine storm.¹³ As IVIG contains antibodies reacting against SARS-CoV-2 antigens,¹⁴ IVIG might inhibit superantigen-mediated T-cell activation and cytokine release.

BIOMARKERS OF IVIG RESPONSE IN COVID-19 PATIENTS ARE ESSENTIAL

From the experience of treating the autoimmune diseases, it is clear that IVIG is not a magic bullet and, understandably, all COVID-19 patients do not respond to IVIG therapy. The current evidence from Shao et al. and other studies suggests that early initiation of IVIG therapy and high-dose infusion could benefit COVID-19 patients. Therefore, studies are required to identify potential biomarkers of IVIG response in COVID-19 patients. As severe and critically ill COVID-19 patients need to receive immediate medical care, healthcare personnel...
Table 1. Overview of clinical studies on the IVIG immunotherapy in COVID-19 patients

| Study          | Location/country                      | Nature of the study | No. of patients | Age (years) | Gender | IVIG dose | Duration of therapy | Additional therapies                                      | Clinical outcome of IVIG therapy                                                                 |
|----------------|---------------------------------------|---------------------|-----------------|-------------|---------|-----------|---------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Shao et al.    | Wuhan, Guangzhou, Shenzhen (China)   | Multicentre retrospective | 174             | IVIG: 61 <sup>6</sup> (50–69) | IVIG – male: 112 (64%) | 0.1–0.5 g kg<sup>-1</sup> day<sup>-1</sup> | 5–15 days | Corticosteroids, antivirals, antibiotics | Improved 28-day mortality                                                                                                                             |
|                |                                       |                     | Non-IVIG: 151    | Non-IVIG: 56 <sup>6</sup> (38–67) | Non-IVIG – male: 77 (51%) | 1 day |                                                     | Improved organ function in critically ill patients                                                   |
|                |                                       |                     |                 | (38–67)     |         |           | 5–15 days |                                                     | Reduced inflammatory response in critically ill patients                                           |
|                |                                       |                     |                 | (50–69)     |         |           | 5–15 days |                                                     | Reduced 60-day mortality in critically ill patients who received early (≤ 7 days postadmission) and high-dose (≥ 15 g day<sup>-1</sup>) IVIG therapy |
|                |                                       |                     |                 | male: 112  | (64%)   |           | 5–15 days |                                                     | Improved organ function in critically ill patients                                                   |
|                |                                       |                     |                 | Non-IVIG: 77 | (51%)   |           | 5–15 days |                                                     | Reduced inflammatory response in critically ill patients                                           |
|                |                                       |                     |                 | male: 77   | (51%)   |           | 5–15 days |                                                     | Reduced 60-day mortality in critically ill patients who received early (≤ 7 days postadmission) and high-dose (≥ 15 g day<sup>-1</sup>) IVIG therapy |
| Zhou et al.    | Hunan (China)                         | Single-centre retrospective | 10             | 51.60 ± 15.46<sup>c</sup> (29–68) | Male: 8 (80%) | 10 g day<sup>-1</sup> followed by 20 g day<sup>-1</sup> | 17–24 days | Corticosteroids, lopinavir, ritonavir, interferon, antibiotics | Improved oxygenation index                                                                   |
|                |                                       |                     |                 |            |         |           | 17–24 days |                                                     | Improved pulmonary lesions (70%)                                                                   |
|                |                                       |                     |                 | (80%)       |         |           | 17–24 days |                                                     | Resolution of disease progression (90%)                                                              |
|                |                                       |                     |                 | Male: 8    | (80%)   |           | 17–24 days |                                                     | Improved clinical status                                                                         |
|                |                                       |                     |                 | male: 8    | (80%)   |           | 17–24 days |                                                     | Resolution of pulmonary lesions                                                                    |
|                |                                       |                     |                 | Male: 8    | (80%)   |           | 17–24 days |                                                     | Return of oxygen saturation and discontinued oxygen supplement                                    |
| Cao et al.     | Wuhan (China)                         | Case series         | 3               | 41.67 ± 12.42<sup>c</sup> (24–56) | Male: 2 (67%) | 25 g day<sup>-1</sup> | 5 days | Methylprednisolone, Moxifloxacin | Improved clinical status                                                                         |
|                |                                       |                     |                 | Male: 2    | (67%)   |           | 5 days | Methylprednisolone, Moxifloxacin | Resolution of pulmonary lesions                                                                    |
|                |                                       |                     |                 | Male: 2    | (67%)   |           | 5 days | Methylprednisolone, Moxifloxacin | Return of oxygen saturation and discontinued oxygen supplement                                    |
|                |                                       |                     |                 | Male: 2    | (67%)   |           | 5 days | Methylprednisolone, Moxifloxacin | In patients who received IVIG therapy ≤ 48 h upon hospital admission                               |
| Sakoulas et al. | San Diego, La Mesa (USA)             | Open-label randomised controlled trial | 16       | IVIG: 16 | IVIG – male: 10 (63%) | 0.5 g kg<sup>-1</sup> day<sup>-1</sup> | 3 days | Methylprednisolone, remdesivir, convalescent plasma | Reduced ICU days                                                                                   |
|                |                                       |                     |                 | Non-IVIG: 51 | Non-IVIG – Male: 10 (59%) | 3 days |                                                     | Reduced ventilator patient days                                                                    |
|                |                                       |                     |                 |                  |                 |           | 3 days |                                                     | Reduced 28-day mortality                                                                           |
|                |                                       |                     |                 |                  |                 |           | 3 days |                                                     | Reduced hospital stays                                                                             |
|                |                                       |                     |                 |                  |                 |           | 3 days |                                                     | Reduced ICU stays                                                                                  |
|                |                                       |                     |                 |                  |                 |           | 3 days |                                                     | Reduced mechanical ventilation                                                                    |
| Xie et al.     | Wuhan (China)                         | Single-centre retrospective | 58             | 63<sup>d</sup> (29–86) | Male: 36 (62%) | 20 g day<sup>-1</sup> | Not precise | Corticosteroids, abidor, moxifloxacin | In patients who received IVIG therapy ≤ 48 h upon hospital admission                               |
|                |                                       |                     |                 | 63<sup>d</sup> (29–86) | Male: 36 (62%) | 20 g day<sup>-1</sup> | Not precise | Corticosteroids, abidor, moxifloxacin | Reduced 28-day mortality                                                                           |
|                |                                       |                     |                 | (29–86)     | (62%)   |           | Not precise | Corticosteroids, abidor, moxifloxacin | Reduced hospital stays                                                                             |
| Mohtadi et al. | Ilam (Iran)                           | Case series         | 5               | 60.4 ± 6.8<sup>e</sup> (50–66) | Male: 1 (20%) | 0.3–0.5 g kg<sup>-1</sup> day<sup>-1</sup> | 5 days | Hydrocortisone, vancomycin, meropenem, azithromycin | Improved clinical symptoms                                                                         |

<sup>a</sup> 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. 2020 | Vol. 9 | e1198 | Page 3
should be able to analyse these predictive biomarkers by easy and rapid methods without sophisticated instruments. Shao et al. and Sakoulas et al. indicate that IVIG decreases IL-6 levels in the plasma. Majority of the studies have also reported that C-reactive protein (CRP) is downregulated following IVIG therapy (Table 1). Although CRP is a general marker of inflammation and is not specific for IVIG therapy, post-IVIG levels of CRP could be investigated further as a biomarker of IVIG response. In addition, pre-IVIG levels of inflammatory mediators such as G-CSF, IFN-γ, IL-1β, and IL-6; the levels of various innate cells (such as monocytes and neutrophils) and adaptive immune cells (such as Th1 and Th17) could also be considered to predict whether patients could benefit from IVIG therapy.15

**PERSPECTIVES**

In addition to COVID-19, SARS-CoV-2 infection is also linked to other complications such as triggering of autoimmune and inflammatory diseases including Kawasaki-like paediatric inflammatory multisystemic syndrome, Guillain–Barré syndrome and idiopathic thrombocytopenic purpura. IVIG therapy is also beneficial in these SARS-CoV-2 infection-associated rare pathological manifestations.16–18 Several phase 2, 3 and 4 clinical trials (NCT04500067, NCT04411667, NCT04480424, NCT04432324, NCT04350580, NCT04400058, NCT04261426, NCT04403269) including double-blind, placebo-controlled, randomised studies are registered in the United States, France, Spain, China and Ukraine. As clinicians are now better equipped with armory of drugs to treat COVID-19 patients and because of the cost associated with IVIG therapy, these registered studies might not get required number of patients to complete the investigation. Also, IVIG is a life-saving drug for primary immunodeficient patients and first-line therapy for many autoimmune and inflammatory diseases. In view of worldwide shortage of IVIG, priority should be given to the patients whose survival is dependent on IVIG while continuing the investigation on COVID-19. Alternatively, in view of broad-spectrum anti-inflammatory properties of IVIG, this therapy could be combined with IL-6- and IL-1-targeted immunotherapies that showed favorable responses19,20 to explore additive or synergistic therapeutic benefits.

| Study | Location/country | Nature of the study | No. of patients | Age (years) | Gender | IVIG dose | Duration of therapy | Additional therapies | Clinical outcome of IVIG therapy |
|-------|------------------|---------------------|----------------|------------|--------|-----------|-------------------|-------------------|----------------------------------|
| Zantah et al. | Philadelphia (USA) | Single-centre retrospective | 51 | 62.7 ± 12.3 | Male: 38 (65%) / Female: 13 (25%) | 0.5 g kg⁻¹ day⁻¹ | 3 days | Anakinra/IVIG: 51 / Tocilizumab: 33 | Improved clinical outcome, reduced ICU requirement and stays, reduced hospital stays and mechanical ventilation duration |

| Laboratory findings | |
|-------------------|---|
| ↓ CK, creatine kinase | |
| ↓ CRP, C-reactive protein | |
| ↓ LDH, lactate dehydrogenase | |

Studies that contain at least three patients were considered.

CK, creatine kinase; CRP, C-reactive protein; ICU, intensive care unit; LDH, lactate dehydrogenase.

Studies with at least three patients were considered.

a Median.

b Mean.
ACKNOWLEDGMENTS

The authors are supported by Agence Nationale de la Recherche, France (Flash COVID-19; ANR-20-COVI-0093-COVIMUNE).

AUTHOR CONTRIBUTIONS

Caroline Galeotti: Writing-original draft; Writing-review & editing. Srini V Kaveri: Writing-review & editing. Jagadeesh Bayry: Conceptualization; Writing-original draft; Writing-review & editing.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Wiersinga WJ, Rhodes A, Cheng AC et al. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 2020; 324: 782–793.
2. Bonam SR, Kaveri SV, Sakuntabhai A et al. Adjunct immunotherapies for the management of severely ill COVID-19 Patients. Cell Rep Med 2020; 1: 100016.
3. Perez EE, Orange JS, Bonilla F et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017; 139: 51–546.
4. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 2017; 29: 491–498.
5. Shao Z, Feng Y, Zhong L et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunology 2020; 9: e1192.
6. Zhou Z-G, Xie S-M, Zhang J et al. Short-term moderate-dose corticosteroid plus immunoglobulin effectively reverses COVID-19 patients who have failed low-dose therapy. Preprints 2020; 2020030065. https://doi.org/10.20944/preprints202003.0065.v1
7. Cao W, Liu X, Bai T et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infect Dis 2020; 7: ofaa102.
8. Sakoulas G, Geriak M, Kullar R et al. Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial. medRxiv 2020. https://doi.org/10.1101/2020.07.20.20157891
9. Xie Y, Cao S, Dong H et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 2020; 81: 318–356.
10. Mohtadi N, Ghayoursi A, Shirazi S et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology 2020; 548: 1–5.
11. Zantah M, Castillo ED, Gangemi AJ et al. Anakinra and intravenous IgG versus tocilizumab in the treatment of COVID-19 pneumonia. medRxiv 2020. https://doi.org/10.1101/2020.09.11.20192401

Figure 1. Possible mechanisms of action of intravenous immunoglobulin (IVIG) in coronavirus disease-19 (COVID-19). It is not yet clear how IVIG benefits severe and critically ill COVID-19 patients. Several studies have reported that IVIG reduces IL-6 and C-reactive protein in the COVID-19 patients suggesting that IVIG targets inflammatory process. Based on the known mechanisms of IVIG demonstrated in autoimmune and inflammatory diseases, and considering the pathophysiology of COVID-19, we propose that IVIG might target cytokine storm in COVID-19 patients by complement scavenging; reciprocal regulation of effector Th1 and Th17 cells, and regulatory T cells (Treg); and inhibition of innate immune cell activation and secretion of inflammatory mediators. DC, dendritic cell; MO, monocyte; MØ, macrophage; NØ, neutrophil.
12. Schwaiger J, Karbiener M, Aberham C et al. No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. *J Infect Dis* 2020; jiaa593: https://doi.org/10.1093/infdis/jiaa593. (epub ahead of print).

13. Cheng MH, Zhang S, Porritt RA et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. *Proc Natl Acad Sci USA* 2020. https://doi.org/10.1073/pnas.2010722117. (epub ahead of print).

14. Diez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. *Immunotherapy* 2020; 12: 571–576.

15. Pouletty M, Borocco C, Ouldali N et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. *Ann Rheum Dis* 2020; 79: 999–1006.

16. Toubiana J, Poirault C, Corsia A et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ* 2020; 369: m2094.

17. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. *Nat Rev Rheumatol* 2020; 16: 413–414.

18. Galeotti C, Kaveri SV, Bayry J. Molecular and immunological biomarkers to predict IVIg response. *Trends Mol Med* 2015; 21: 145–147.

19. Guaraldi G, Meschiari M, Cozzi-Lepri A et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol* 2020; 2: e474–e484.

20. Huet T, Beaussier H, Voisin O et al. Anakinra for severe forms of COVID-19: a cohort study. *Lancet Rheumatol* 2020; 2: e393–e400.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.